AgomAb Therapeutics NV (AGMB)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Agomab (AGMB) Reports AGMB-445 Phase 1b Trial Progress and €64.8M Cash Position
# 🧾 What This Document Is This is AgomAb Therapeutics' **20-F Annual Report**, a comprehensive filing required by the U.S. Securities and Exchange Commission (SEC) for foreign companies like this Belgian biotech. Think of it as the company's official annual "check-up" for U.S. investors, covering
SEC filings
All filings →Insider trades
All insider trades →AgomAb Therapeutics NV has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for AgomAb Therapeutics NV in this window.
People at AgomAb Therapeutics NV
All people →Quarterly financials
Full financials →No quarterly financials have been ingested for AgomAb Therapeutics NV.